Leg­end rais­es $200M from pri­vate in­vestor af­ter con­fer­ence leaks PhI­II Carvyk­ti da­ta

A day af­ter a leaked da­ta pre­sen­ta­tion show­ing pos­i­tive Phase III re­sults for Leg­end Biotech’s CAR-T treat­ment Carvyk­ti, the com­pa­ny said it has raised $200 mil­lion in a pri­vate stock sale, based on the strength of the da­ta.

Leg­end is part­nered with John­son & John­son on the cell ther­a­py, which is al­ready ap­proved as a fifth-line treat­ment for mul­ti­ple myelo­ma. Da­ta from the tri­al showed that Carvyk­ti was as­so­ci­at­ed with a 74% re­duc­tion in the risk of mul­ti­ple myelo­ma pro­gres­sion or death.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER